MANCHESTER, N.H.--(BUSINESS WIRE)--Boston Therapeutics, Inc. (BTI), a public company registered with the SEC and a developer of diabetes therapeutics, announced today the completion of a trial in healthy volunteers performed at the University of Sydney on SUGARDOWN™, a dietary supplement designed to reduce post-meal elevation of blood glucose.
